SUPPLEMENTARY FILE LEGENDS
. 54 gene panel (ctDNA), identifies potential tumor-related genomic alterations within 54 cancer-related genes including amplifications in ERBB2, EGFR, and MET. Only non-synonymous alterations were analyzed (N = 4 samples). Table 2 . 68 gene panel (ctDNA), comprising amplifications in 16 genes as well as some fusions and indels. Only non-synonymous alterations were analyzed (N = 44 samples). Table 5 . Complete list of genomic alterations (ctDNA and tissue DNA) as well as timing of molecular profiling among patients with colorectal cancer (N=94). Table 6 . Concordance between ctDNA and tissue testing (N=76 patients) Supplemental Table 7 . Overall Survival Analyses depending on the Tissue NGS results (N = 76) Table 2 . 68 gene panel (ctDNA), comprising amplifications in 16 genes as well as some fusions and indels. Only non-synonymous alterations were analyzed (N = 44 samples). BRAF  BRCA1  BRCA2  CCND1  CCND2  CCND1  CCND2  FGFR2  ERBB2*  CCNE1  CDH1  CDK4  CDK6  CDKN2A CDKN2B CCNE1  CDK4  FGFR3  MET**  CTNNB1 EGFR  ERBB2  ESR1  EZH2  FBXW7  CDK6  EGFR  NTRK1  FGFR1  FGFR2 FGFR3  GATA3  GNA11  GNAQ  ERBB2  FGFR1  RET  GNAS  HNF1A HRAS  IDH1  IDH2  JAK2  FGFR2  KIT  ROS1  JAK3  KIT  KRAS  MAP2K1 MAP2K2 MET  KRAS  MET  MLH1  MPL  MYC  NF1  NFE2L2  NOTCH1 MYC  PDGFRA  NPM1  NRAS  NTRK1  PDGFRA Amplification, CDKN2A  G35W, APC S1419R,  NOTCH1 I451M, FBXW7  Q44H, ALK S47L, AR  K63Q, AR L635R, TP53  Q317K, SMO V404E,  NOTCH1 E981G, NOTCH1  G2130V, ABL1 H396N,  ALK K343T, ERBB2  D873G, NOTCH1 G114V,  HRAS 
Supplemental

POINT MUTATIONS (68 genes)
AMPLIFICATIONS
Negative
N=2 N=57
Negative concordance (-/-): alteration was not detected in both tests. Positive concordance (+/+): alteration was detected in both tests. Overall concordance percentages included negative and positive concordant cases, i.e. when both the tissue and the ctDNA were negative or positive. Only alterations detected in ≥ 15 patients in the 76 patients with both types of test were included in this analysis. Kappa values range from κ = 1 (perfect agreement) to κ = 0 (no agreement other than would be expected by chance). SE=Standard Error. * 2-sided Chi-Square test, compares the % of overall concordance between patients with biopsy interval time ≤ or > 6 months. Table 2 with N≥ 10 were included in the analysis. EGFR, ERBB2 and MYC alterations were not included due to the low number of patients harboring these alterations (N= 1, 4 and 8 respectively).
Comparison of concordance rates for patients with both ctDNA and tissue testing based on time interval
**Bonferroni corrected P-value level of significance was 0.025 (corrected for multiple comparisons). Only the variables with P<0.025 was considered as significant.
Abbreviations: ctDNA = circulating tumor DNA; NR = not reached Supplemental Notes: The number after the alteration represents the percentage of ctDNA detected. For PFS, a "+" sign means that the treatment is ongoing and patients did not progress yet. Patients whose best response is "too early" had an ongoing therapy with a stable disease < 6 months.
Abbreviations: 5FU: fluorouracil; FOLFIRI: folinic acid, fluouracil, irinotecan; FOLFOX: folinic acid, fluouracil, oxaliplatin; FOLFOXIRI: folinic acid, fluouracil, oxaliplatin, and irinotecan; PFS: progression-free survival; PD: progressive disease; PR: partial response; SD; stable disease. Logistic regression analyses for the response rate; log rang tests and cox regression analyses for PFS and OS.
Supplemental
Abbreviations: CR = complete response; OS = overall survival; PFS = progression-free survival; PR = partial response; SD = stable disease 24 Supplemental Figure 1 . Concordance between ctDNA and tissue DNA analyses among commonly altered genomic alterations
